{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:23:31Z","timestamp":1787027011784,"version":"build-2736575974"},"reference-count":135,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T00:00:00Z","timestamp":1537920000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2018.01049","type":"journal-article","created":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T10:29:14Z","timestamp":1537957754000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":36,"title":["Clozapine Pharmacogenetic Studies in Schizophrenia: Efficacy and Agranulocytosis"],"prefix":"10.3389","volume":"9","author":[{"given":"Shusuke","family":"Numata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehiro","family":"Umehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Ohmori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,9,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/mp.2010.14","article-title":"Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs","volume":"16","author":"Adkins","year":"2011","journal-title":"Mol. Psychiatry"},{"key":"B2","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ijcard.2014.07.103","article-title":"A systematic review of clozapine induced cardiomyopathy","volume":"176","author":"Alawami","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1056\/NEJM199307153290303","article-title":"Clozapine-induced agranulocytosis. Incidence and risk factors in the United States","volume":"329","author":"Alvir","year":"1993","journal-title":"N. Engl. J. Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1017\/S1461145798001023","article-title":"An association between clozapine-induced agranulocytosis in schizophrenics and HLA-DQB1*0201","volume":"1","author":"Amar","year":"1998","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/JCP.0b013e31821084dc","article-title":"Agranulocytosis related to clozapine in monozygotic twins and association with allelic variants of multidrug resistance gene MDR1","volume":"31","author":"Anil Yagcioglu","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/JCP.0000000000000495","article-title":"Relation of the allelic variants of multidrug resistance gene to agranulocytosis associated with clozapine","volume":"36","author":"Anil Yagcioglu","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/sj.mp.4000652","article-title":"The serotonin transporter and clozapine response","volume":"5","author":"Arranz","year":"","journal-title":"Mol. Psychiatry"},{"key":"B8","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0140-6736(95)92168-0","article-title":"Association between clozapine response and allelic variation in 5-HT2A receptor gene","volume":"346","author":"Arranz","year":"","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0304-3940(96)13094-9","article-title":"Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine","volume":"217","author":"Arranz","year":"1996","journal-title":"Neurosci. Lett."},{"key":"B10","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/j.1365-2125.1995.tb04471.x","article-title":"Cytochrome P4502D6 genotype does not determine response to clozapine","volume":"39","author":"Arranz","year":"","journal-title":"Br. J. Clin. Pharmacol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/00008571-199812000-00004","article-title":"Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response","volume":"8","author":"Arranz","year":"","journal-title":"Pharmacogenetics"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/S0140-6736(00)02221-2","article-title":"Pharmacogenetic prediction of clozapine response","volume":"355","author":"Arranz","year":"","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/sj.mp.4000348","article-title":"Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine","volume":"3","author":"Arranz","year":"","journal-title":"Mol. Psychiatry"},{"key":"B14","doi-asserted-by":"publisher","first-page":"458","DOI":"10.4088\/JCP.09m05527yel","article-title":"Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis","volume":"72","author":"Athanasiou","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.5455\/bcp.20110622071701","article-title":"CYP1A2*1F polymorphism decreases clinical response to clozapine in patients with schizophrenia","volume":"21","author":"Balibey","year":"2011","journal-title":"Bull. Clin. Psychopharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/ajmg.b.30770","article-title":"Lack of association between DRD3 gene polymorphism and response to clozapine in Turkish schizoprenia patients","author":"Barlas","year":"2009","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1097\/00001756-200006260-00042","article-title":"Association analysis of the 5-HT5A gene in depression, psychosis and antipsychotic response","volume":"11","author":"Birkett","year":"2000","journal-title":"Neuroreport"},{"key":"B18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2217\/pgs.14.150","article-title":"COMT Val158Met and 5-HT1A-R\u22121019 C\/G polymorphisms: effects on the negative symptom response to clozapine","volume":"16","author":"Bosia","year":"2015","journal-title":"Pharmacogenomics"},{"key":"B19","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.schres.2016.06.032","article-title":"The role of the ITIH3 rs2535629 variant in antipsychotic response","volume":"176","author":"Brandl","year":"2016","journal-title":"Schizophr. Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2165\/00002018-199200071-00004","article-title":"No direct clinical relevance of the human leucocyte antigen (HLA) system in clozapine-induced agranulocytosis","volume":"7","author":"Claas","year":"1992","journal-title":"Drug Saf."},{"key":"B21","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1182\/blood.V86.10.3835.bloodjournal86103835","article-title":"The major histocompatibility complex region marked by HSP70-1 and HSP70-2 variants is associated with clozapine-induced agranulocytosis in two different ethnic groups","volume":"86","author":"Corzo","year":"1995","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/S0140-6736(12)62129-1","article-title":"Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis","volume":"381","year":"2013","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2174\/157488612800492681","article-title":"Update on the adverse effects of clozapine: focus on myocarditis","volume":"7","author":"De Berardis","year":"2012","journal-title":"Curr. Drug Saf."},{"key":"B24","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.schres.2015.10.018","article-title":"The CYP1A2\u2212163C > A polymorphism is associated with super-refractory schizophrenia","volume":"169","author":"de Brito","year":"2015","journal-title":"Schizophr. Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/sj.tpj.6500423","article-title":"Clozapine-induced agranulocytosis in schizophrenic Caucasians: confirming clues for associations with human leukocyte class I and II antigens","volume":"7","author":"Dettling","year":"2007","journal-title":"Pharmacogenomics J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1001\/archpsyc.58.1.93","article-title":"Genetic determinants of clozapine-induced agranulocytosis: recent results of HLA subtyping in a non-jewish caucasian sample","volume":"58","author":"Dettling","year":"","journal-title":"Arch. Gen. Psychiatry"},{"key":"B27","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1055\/s-2000-8359","article-title":"Clozapine-induced agranulocytosis and hereditary polymorphisms of clozapine metabolizing enzymes: no association with myeloperoxidase and cytochrome P4502D6","volume":"33","author":"Dettling","year":"2000","journal-title":"Pharmacopsychiatry"},{"key":"B28","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/00008571-200103000-00004","article-title":"Further evidence of human leukocyte antigen-encoded susceptibility to clozapine-induced agranulocytosis independent of ancestry","volume":"11","author":"Dettling","year":"","journal-title":"Pharmacogenetics"},{"key":"B29","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/FPC.0000000000000213","article-title":"The identification of novel genetic variants associated with antipsychotic treatment response outcomes in first-episode schizophrenia patients","volume":"26","author":"Dr\u00f6gem\u00f6ller","year":"2016","journal-title":"Pharmacogenet. Genomics"},{"key":"B30","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1097\/01.jcp.0000116646.91923.2f","article-title":"Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene","volume":"24","author":"Eap","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"key":"B31","doi-asserted-by":"crossref","first-page":"323","DOI":"10.31887\/DCNS.2016.18.3\/jbishop","article-title":"Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations","volume":"18","author":"Eum","year":"2016","journal-title":"Dialogues Clin. Neurosci."},{"key":"B32","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.pnpbp.2018.05.007","article-title":"Pharmacogenetic tests to guide drug treatment in depression: comparison of the available testing kits and clinical trials","volume":"86","author":"Fabbri","year":"2018","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"B33","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/(SICI)1096-8628(19960920)67:5<455::AID-AJMG3>3.0.CO;2-J","article-title":"Assessment of association of D3 dopamine receptor MscI polymorphism with schizophrenia: analysis of symptom ratings, family history, age at onset, and movement disorders","volume":"67","author":"Gaitonde","year":"1996","journal-title":"Am. J. Med. Genet"},{"key":"B34","doi-asserted-by":"publisher","first-page":"730956","DOI":"10.1155\/2014\/730956","article-title":"The potential utility of pharmacogenetic testing in psychiatry","volume":"2014","author":"Gardner","year":"2014","journal-title":"Psychiatry J"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41397-017-0004-2","article-title":"Cost-effectiveness of HLA-DQB1\/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine","author":"Girardin","year":"2018","journal-title":"Pharmacogenomics J."},{"key":"B36","doi-asserted-by":"publisher","first-page":"4757","DOI":"10.1038\/ncomms5757","article-title":"Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles","volume":"5","author":"Goldstein","year":"2014","journal-title":"Nat. Commun."},{"key":"B37","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.euroneuro.2015.12.035","article-title":"Pharmacogenetics of clozapine response and induced weight gain: a comprehensive review and meta-analysis","volume":"26","author":"Gressier","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0920-9964(02)00205-0","article-title":"Novel mutations in 5-HT3A and 5-HT3B receptor genes not associated with clozapine response","volume":"58","author":"Guti\u00e9rrez","year":"2002","journal-title":"Schizophr. Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.pnpbp.2003.09.007","article-title":"Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality","volume":"27","author":"Heresco-Levy","year":"2003","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"B40","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1097\/00041444-200112000-00007","article-title":"Association analysis for NMDA receptor subunit 2B (GRIN2B) genetic variants and psychopathology and clozapine response in schizophrenia","volume":"11","author":"Hong","year":"2001","journal-title":"Psychiatr. Genet."},{"key":"B41","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/136515001300225231","article-title":"Clozapine-induced concordant agranulocytosis in monozygotic twins","volume":"5","author":"Hor\u00e1cek","year":"2001","journal-title":"Int. J. Psychiatry Clin. Pract."},{"key":"B42","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2217\/pgs.15.155","article-title":"Preliminary evidence for association of genome-wide significant DRD2 schizophrenia risk variant with clozapine response","volume":"17","author":"Huang","year":"2016","journal-title":"Pharmacogenomics"},{"key":"B43","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/pcn.12508","article-title":"Role of cytokine changes in clozapine-induced fever: a cohort prospective study","volume":"71","author":"Hung","year":"2017","journal-title":"Psychiatry Clin. Neurosci."},{"key":"B44","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s00213-005-2223-5","article-title":"Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory\/intolerant populations","volume":"181","author":"Hwang","year":"2005","journal-title":"Psychopharmacology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1177\/0269881106072341","article-title":"Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment response","volume":"21","author":"Hwang","year":"2007","journal-title":"J. Psychopharmacol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.euroneuro.2005.09.004","article-title":"Dopamine D2 receptor gene variants and quantitative measures of positive and negative symptom response following clozapine treatment","volume":"16","author":"Hwang","year":"2006","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2217\/pgs.10.182","article-title":"Gene-gene interaction analyses between NMDA receptor subunit and dopamine receptor gene variants and clozapine response","volume":"12","author":"Hwang","year":"2011","journal-title":"Pharmacogenomics"},{"key":"B48","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.pnpbp.2011.11.018","article-title":"Dopamine D4 and D5 receptor gene variant effects on clozapine response in schizophrenia: replication and exploration","volume":"37","author":"Hwang","year":"2012","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"B49","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/tpj.2009.65","article-title":"Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant","volume":"10","author":"Hwang","year":"2010","journal-title":"Pharmacogenomics J."},{"key":"B50","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/JCP.0000000000000268","article-title":"Genetic overlap between antipsychotic response and susceptibility to schizophrenia","volume":"35","author":"Ikeda","year":"2015","journal-title":"J. Clin. Psychopharmacol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"6547","DOI":"10.1002\/sim.3420","article-title":"Methodological quality of pharmacogenetic studies: issues of concern","volume":"27","author":"Jorgensen","year":"2008","journal-title":"Stat. Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/sj.mp.4000729","article-title":"Dopamine D4 receptor 48-bp repeat polymorphism: no association with response to antipsychotic treatment, but association with catatonic schizophrenia","volume":"5","author":"Kaiser","year":"2000","journal-title":"Mol. Psychiatry"},{"key":"B53","first-page":"57","article-title":"Functional neuroimaging and pharmacogenetic studies of clozapine's action at dopamine receptors","volume":"55","author":"Kerwin","year":"1994","journal-title":"J. Clin. Psychiatry"},{"key":"B54","doi-asserted-by":"publisher","first-page":"E632","DOI":"10.3390\/ijms18030632","article-title":"Effect of clozapine on DNA methylation in peripheral leukocytes from patients with treatment-resistant schizophrenia","volume":"18","author":"Kinoshita","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.jpsychires.2010.04.003","article-title":"Influence of serotonin transporter gene polymorphisms on clozapine response in Brazilian schizophrenics","volume":"44","author":"Kohlrausch","year":"2010","journal-title":"J. Psychiatr. Res."},{"key":"B56","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0924-977X(96)00380-X","article-title":"Dopamine D4 receptor gene polymorphisms: relation to ethnicity, no association with schizophrenia and response to clozapine in Israeli subjects","volume":"7","author":"Kohn","year":"1997","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/00004714-200102000-00002","article-title":"Human leukocyte antigen-A1 predicts a good therapeutic response to clozapine with a low risk of agranulocytosis in patients with schizophrenia","volume":"21","author":"Lahdelma","year":"2001","journal-title":"J. Clin. Psychopharmacol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.schres.2016.12.017","article-title":"Analysis of differential gene expression mediated by clozapine in human postmortem brains","volume":"185","author":"Lee","year":"2017","journal-title":"Schizophr. Res."},{"key":"B59","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1097\/JCP.0b013e31825ac35c","article-title":"Association study of 27 annotated genes for clozapine pharmacogenetics: validation of preexisting studies and identification of a new candidate gene, ABCB1, for treatment response","volume":"32","author":"Lee","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1038\/mp.2016.97","article-title":"Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia","volume":"22","author":"Legge","year":"2017","journal-title":"Mol. Psychiatry"},{"key":"B61","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/FPC.0000000000000250","article-title":"Genome-wide association study of paliperidone efficacy","volume":"27","author":"Li","year":"2017","journal-title":"Pharmacogenet. Genomics"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1176\/ajp.151.12.1744","article-title":"Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome","volume":"151","author":"Lieberman","year":"1994","journal-title":"Am. J. Psychiatry"},{"key":"B63","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1001\/archpsyc.1990.01810220061007","article-title":"HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia","volume":"47","author":"Lieberman","year":"1990","journal-title":"Arch. Gen. Psychiatry"},{"key":"B64","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/00001756-199901180-00011","article-title":"No evidence for association of serotonin-2A receptor variant (102T\/C) with schizophrenia or clozapine response in a Chinese population","volume":"10","author":"Lin","year":"1999","journal-title":"Neuroreport"},{"key":"B65","first-page":"92","article-title":"Allelic variation in the promoter region of the dopamine D2 receptor gene and clozapine response. Schizoohr","volume":"36","author":"Malhotra","year":"1999","journal-title":"Res"},{"key":"B66","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/sj.mp.4000288","article-title":"The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response","volume":"3","author":"Malhotra","year":"1998","journal-title":"Mol. Psychiatry"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1176\/ajp.153.8.1092","article-title":"Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine","volume":"153","author":"Malhotra","year":"","journal-title":"Am. J. Psychiatry"},{"key":"B68","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1097\/00001756-199609020-00007","article-title":"Clozapine response and the 5HT2C Cys23Ser polymorphism","volume":"7","author":"Malhotra","year":"","journal-title":"Neuroreport"},{"key":"B69","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0893-133X(98)00007-4","article-title":"Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients","volume":"19","author":"Masellis","year":"1998","journal-title":"Neuropsychopharmacology"},{"key":"B70","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0920-9964(00)00016-5","article-title":"Lack of association between the T\u2013&gt;C 267 serotonin 5-HT6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia","volume":"47","author":"Masellis","year":"2001","journal-title":"Schizophr. Res."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/S0140-6736(95)91785-3","article-title":"Genetic variation of 5-HT2A receptor and response to clozapine","volume":"346","author":"Masellis","year":"1995","journal-title":"Lancet"},{"key":"B72","first-page":"1163","article-title":"Clinical pharmacology of atypical antipsychotics: an update","volume":"13","author":"Mauri","year":"2014","journal-title":"EXCLI J."},{"key":"B73","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/mp.2009.89","article-title":"Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics","volume":"16","author":"McClay","year":"2011","journal-title":"Mol. Psychiatry"},{"key":"B74","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/00004850-199909000-00005","article-title":"Human leukocyte antigen typing, response to neuroleptics, and clozapine-induced agranulocytosis in jewish Israeli schizophrenic patients","volume":"14","author":"Meged","year":"1999","journal-title":"Int. Clin. Psychopharmacol."},{"key":"B75","first-page":"47","article-title":"An overview of the mechanism of action of clozapine","volume":"55","author":"Meltzer","year":"1994","journal-title":"J. Clin. Psychiatry"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1185\/03007999709113338","article-title":"Treatment-resistant schizophrenia\u2013the role of clozapine","volume":"14","author":"Meltzer","year":"1997","journal-title":"Curr. Med. Res. Opin."},{"key":"B77","first-page":"117","article-title":"Plasma clozapine concentrations as a predictor of clinical response: a follow-up study","volume":"55","author":"Miller","year":"1994","journal-title":"J. Clin. Psychiatry"},{"key":"B78","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1097\/01.jcp.0000177551.13714.33","article-title":"Drug-induced agranulocytosis: impact of different fcgamma receptor polymorphisms?","volume":"25","author":"Mosyagin","year":"2005","journal-title":"J. Clin. Psychopharmacol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1097\/01.jcp.0000144891.52858.a6","article-title":"Impact of myeloperoxidase and NADPH-oxidase polymorphisms in drug-induced agranulocytosis","volume":"24","author":"Mosyagin","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12898","author":"Myles","year":"2018","journal-title":"Acta Psychiatr. Scand"},{"key":"B81","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.schres.2016.10.012","article-title":"Differential gene expression profiles in neurons generated from lymphoblastoid B-cell line-derived iPS cells from monozygotic twin cases with treatment-resistant schizophrenia and discordant responses to clozapine","volume":"181","author":"Nakazawa","year":"2017","journal-title":"Schizophr. Res."},{"key":"B82","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0140-6736(95)92756-5","article-title":"Genetic variation of the 5-HT2A receptor and response to clozapine","volume":"346","author":"N\u00f6then","year":"1995","journal-title":"Lancet"},{"key":"B83","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1046\/j.1399-0039.2003.00133.x","article-title":"NQO2 gene is associated with clozapine-induced agranulocytosis","volume":"62","author":"Ostrousky","year":"2003","journal-title":"Tissue Antigens"},{"key":"B84","first-page":"231","article-title":"Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients","volume":"148","author":"Perry","year":"1991","journal-title":"Am. J. Psychiatry"},{"key":"B85","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1080\/15622975.2017.1347712","article-title":"CYP2C19*17 protects against metabolic complications of clozapine treatment","volume":"18","author":"Piatkov","year":"2017","journal-title":"World J. Biol. Psychiatry"},{"key":"B86","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/sj.mp.4001191","article-title":"D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine","volume":"8","author":"Potkin","year":"2003","journal-title":"Mol. Psychiatry"},{"key":"B87","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/FPC.0000000000000314","article-title":"Gene-gene interaction between DRD4 and COMT modulates clinical response to clozapine in treatment-resistant schizophrenia","volume":"28","author":"Rajagopal","year":"2018","journal-title":"Pharmacogenet. Genomics"},{"key":"B88","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/YIC.0b013e32835ac9da","article-title":"Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia","volume":"28","author":"Rajkumar","year":"","journal-title":"Int. Clin. Psychopharmacol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00213-012-2773-2","article-title":"Outcome definitions and clinical predictors influence pharmacogenetic associations between HTR3A gene polymorphisms and response to clozapine in patients with schizophrenia","volume":"224","author":"Rajkumar","year":"2012","journal-title":"Psychopharmacology"},{"key":"B90","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1601-5215.2012.00638.x","article-title":"Association between CYP1A2 gene single nucleotide polymorphisms and clinical responses to clozapine in patients with treatment-resistant schizophrenia","volume":"25","author":"Rajkumar","year":"","journal-title":"Acta Neuropsychiatr"},{"key":"B91","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1001\/archpsyc.1994.03950110072009","article-title":"Allelic variation in the D4 dopamine receptor (DRD4) gene does not predict response to clozapine","volume":"51","author":"Rao","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"key":"B92","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1097\/00001756-199705260-00040","article-title":"Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor","volume":"8","author":"Rietschel","year":"1997","journal-title":"Neuroreport"},{"key":"B93","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0893-133X(96)00090-5","article-title":"Efficacy and side-effects of clozapine: testing for association with allelic variation in the dopamine D4 receptor gene","volume":"15","author":"Rietschel","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"B94","doi-asserted-by":"publisher","first-page":"cvd.2012.012001","DOI":"10.1258\/cvd.2012.012001","article-title":"Promises and challenges of pharmacogenetics: an overview of study design, methodological and statistical issues","volume":"1","author":"Ross","year":"2012","journal-title":"JRSM Cardiovasc. Dis."},{"key":"B95","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/S2215-0366(15)00553-2","article-title":"Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach","volume":"3","author":"Ruderfer","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"B96","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1016\/j.biopsych.2016.12.009","article-title":"transethnic replication study to assess the association between clozapine-induced agranulocytosis\/granulocytopenia and genes at 12p12.2 in a Japanese population","volume":"82","author":"Saito","year":"2017","journal-title":"Biol. Psychiatry"},{"key":"B97","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.biopsych.2015.12.006","article-title":"pharmacogenomic study of clozapine-induced agranulocytosis\/granulocytopenia in a Japanese population","volume":"80","author":"Saito","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"B98","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0924-977X(99)00044-9","article-title":"Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakastani patients","volume":"10","author":"Scharfetter","year":"1999","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nature13595","article-title":"Biological insights from 108 schizophrenia-associated genetic loci","volume":"511","year":"2014","journal-title":"Nature"},{"key":"B100","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/S0140-6736(05)74176-3","article-title":"Pharmacogenetics of the clozapine response","volume":"356","author":"Schumacher","year":"2000","journal-title":"Lancet"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.pnpbp.2007.06.002","article-title":"Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia","volume":"31","author":"Semiz","year":"2007","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"B102","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/0140-6736(93)92594-J","article-title":"Dopamine D4 receptor subtypes and response to clozapine","volume":"341","author":"Shaikh","year":"1993","journal-title":"Lancet"},{"key":"B103","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/ajmg.1320600611","article-title":"Analysis of clozapine response and polymorphisms of the dopamine D4 receptor gene (DRD4) in schizophrenic patients","volume":"60","author":"Shaikh","year":"1995","journal-title":"Am. J. Med. Genet."},{"key":"B104","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1007\/BF02346178","article-title":"Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia","volume":"97","author":"Shaikh","year":"1996","journal-title":"Hum. Genet."},{"key":"B105","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1192\/bjp.bp.115.177261","article-title":"Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis","volume":"209","author":"Siskind","year":"2016","journal-title":"Br. J. Psychiatry"},{"key":"B106","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1177\/0706743717718167","article-title":"Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis","volume":"62","author":"Siskind","year":"2017","journal-title":"Can. J. Psychiatry"},{"key":"B107","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00001756-199512000-00041","article-title":"Association between clozapine response and allelic variation in the 5-HT2C receptor gene","volume":"7","author":"Sodhi","year":"1995","journal-title":"Neuroreport"},{"key":"B108","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1097\/FPC.0b013e328337ce3e","article-title":"Influence of serotonin 3A and 3B receptor genes on clozapine treatment response in schizophrenia","volume":"20","author":"Souza","year":"2010","journal-title":"Pharmacogenet. Genomics"},{"key":"B109","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/hup.2519","article-title":"Genetic association analysis of N-methyl-D-aspartate receptor subunit gene GRIN2B and clinical response to clozapine","volume":"31","author":"Taylor","year":"2016","journal-title":"Hum. Psychopharmacol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000449224","article-title":"Pharmacogenetic analysis of functional glutamate system gene variants and clinical response to clozapine","volume":"2","author":"Taylor","year":"2017","journal-title":"Mol Neuropsychiatry"},{"key":"B111","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1176\/appi.ajp.158.5.816","article-title":"Clozapine and weight gain","volume":"158","author":"Theisen","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"B112","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1159\/000119351","article-title":"Human leukocyte antigen system in clozapine-induced agranulocytosis","volume":"36","author":"Theodoropoulou","year":"1997","journal-title":"Neuropsychobiology"},{"key":"B113","first-page":"505","article-title":"Point: population stratification: a problem for case-control studies of candidate-gene associations?","volume":"11","author":"Thomas","year":"2002","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"B114","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/mp.2013.74","article-title":"Exome sequence analysis of Finnish patients with clozapine-induced agranulocytosis","volume":"19","author":"Tiwari","year":"2014","journal-title":"Mol. Psychiatry"},{"key":"B115","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0920-9964(99)00170-X","article-title":"Association study of a functional serotonin transporter gene polymorphism with schizophrenia, psychopathology and clozapine response","volume":"44","author":"Tsai","year":"2000","journal-title":"Schizophr. Res."},{"key":"B116","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1182\/blood.V89.11.4167","article-title":"Tumor necrosis factor constellation polymorphism and clozapine-induced agranulocytosis in two different ethnic groups","volume":"89","author":"Turbay","year":"1997","journal-title":"Blood"},{"key":"B117","doi-asserted-by":"crossref","first-page":"420","DOI":"10.4088\/JCP.v63n0508","article-title":"Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia","volume":"63","author":"Umbricht","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"B118","doi-asserted-by":"publisher","first-page":"410","DOI":"10.2174\/138920008784746373","article-title":"Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions","volume":"9","author":"Urichuk","year":"2008","journal-title":"Curr. Drug Metab."},{"key":"B119","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1046\/j.1365-2370.1998.00091.x","article-title":"HLA-B38 and clozapine-induced agranulocytosis in Israeli Jewish schizophrenic patients","volume":"25","author":"Valevski","year":"1998","journal-title":"Eur. J. Immunogenet."},{"key":"B120","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/tpj.2016.32","article-title":"Genetic risk factors for clozapine-induced neutropenia and agranulocytosis in a Dutch psychiatric population","volume":"17","author":"van der Weide","year":"2017","journal-title":"Pharmacogenomics J."},{"key":"B121","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(96)91594-9","article-title":"Monozygotic twins concordant for response to clozapine","volume":"347","author":"Vojvoda","year":"1996","journal-title":"Lancet"},{"key":"B122","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/1471-244X-14-102","article-title":"Clozapine: a review of clinical practice guidelines and prescribing trends","volume":"14","author":"Warnez","year":"2014","journal-title":"BMC Psychiatry"},{"key":"B123","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.psychres.2004.02.018","article-title":"Clozapine: weight gain in a pair of monozygotic twins concordant for schizophrenia and mild mental retardation","volume":"133","author":"Wehmeier","year":"2005","journal-title":"Psychiatry Res"},{"key":"B124","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/MOH.0000000000000391","article-title":"Clozapine-induced agranulocytosis\/granulocytopenia: mechanisms and monitoring","volume":"25","author":"Wicinski","year":"2018","journal-title":"Curr. Opin. Hematol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.schres.2006.10.002","article-title":"COMT val108\/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia","volume":"90","author":"Woodward","year":"2007","journal-title":"Schizophr. Res."},{"key":"B126","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.pnpbp.2010.05.017","article-title":"Pharacogenetic effects of dopamine transporter gene polymorphisms on response to chlorpromazine and clozapine and on extrapyramidal syndrome in schizophrenia","volume":"34","author":"Xu","year":"2010","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"B127","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/tpj.2015.61","article-title":"Association studies of genomic variants with treatment response to risperidone, clozapine, quetiapine and chlorpromazine in the Chinese Han population","volume":"16","author":"Xu","year":"2016","journal-title":"Pharmacogenomics J."},{"key":"B128","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/pcn.12505","article-title":"Optimizing outcomes in clozapine rechallenge following neutropenia using human leukocyte antigen typing: a case report","volume":"71","author":"Yamaki","year":"2017","journal-title":"Psychiatry Clin. Neurosci."},{"key":"B129","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.neulet.2014.08.052","article-title":"Changes in plasma D-serine, L-serine, and glycine levels in treatment-resistant schizophrenia before and after clozapine treatment","volume":"582","author":"Yamamori","year":"2014","journal-title":"Neurosci. Lett."},{"key":"B130","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.neulet.2013.09.059","article-title":"Plasma levels of mature brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) in treatment-resistant schizophrenia treated with clozapine","volume":"556","author":"Yamamori","year":"2013","journal-title":"Neurosci. Lett."},{"key":"B131","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S2215-0366(18)30049-X","article-title":"Five novel loci associated with antipsychotic treatment response in patients with schizophrenia: a genome-wide association study","volume":"5","author":"Yu","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"B132","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1097\/00001756-199904260-00014","article-title":"Serotonin-6 receptor variant (C267T) and clinical response to clozapine","volume":"10","author":"Yu","year":"1999","journal-title":"Neuroreport"},{"key":"B133","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1159\/000054871","article-title":"Evidence for an association between polymorphism in the serotonin-2A receptor variant (102T\/C) and increment of N100 amplitude in schizophrenics treated with clozapine","volume":"43","author":"Yu","year":"2001","journal-title":"Neuropsychobiology"},{"key":"B134","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1182\/blood.V86.3.1177.1177","article-title":"HLA associations in clozapine-induced agranulocytosis","volume":"86","author":"Yunis","year":"1995","journal-title":"Blood"},{"key":"B135","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1080\/00207450590957863","article-title":"Dopamine D4 receptor gene exon III polymorphism and interindividual variation in response to clozapine","volume":"115","author":"Zhao","year":"2005","journal-title":"Int. J. Neurosci."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.01049\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T22:39:21Z","timestamp":1605047961000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.01049\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,26]]},"references-count":135,"alternative-id":["10.3389\/fphar.2018.01049"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2018.01049","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,26]]},"article-number":"1049"}}